In Brief: Teva/Marion Merrell Dow
Teva/Marion Merrell Dow: Sign letter of intent to collaborate on late-stage development and North American marketing of Teva's Copaxone (copolymer-1) for multiple sclerosis. Teva announced in October after Phase III results were released that it expects to submit the Copaxone NDA to FDA and to make comparable regulatory filings in other major markets "by the middle of 1995" ("The Pink Sheet" Oct. 17, 1994, T&G-4). Copaxone is being studied for its ability to lessen the number of exacerbations and the extent of disability in MS patients with the relapsing/remitting form of the disease. The drug is available in the U.S. under a Treatment IND through Teva's Lemmon generics subsidiary...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth